Journal of the Korean Association of Oral and Maxillofacial Surgeons

  • 제40권6호
  • /
  • Pages.291-296
  • /
  • 2014
  • /
  • 2234-7550(pISSN)
  • /
  • 2234-5930(eISSN)
대한구강악안면외과학회 (The Korean Association of Oral and Maxillofacial Surgeons)
권호 표지
DOI QR코드

DOI QR Code

Effect of recombinant human bone morphogenetic protein-2 on bisphosphonate-treated osteoblasts

  • Kwon, Taek-Kyun (Department of Oral and Maxillofacial Surgery, School of Dentistry, Pusan National University) ;
  • Song, Jae-Min (Department of Oral and Maxillofacial Surgery, School of Dentistry, Pusan National University) ;
  • Kim, In-Ryoung (Department of Oral Anatomy and Cell Biology, School of Dentistry, Pusan National University) ;
  • Park, Bong-Soo (Department of Oral Anatomy and Cell Biology, School of Dentistry, Pusan National University) ;
  • Kim, Chul-Hoon (Department of Dentistry, Dong-A University Hospital) ;
  • Cheong, In-Kyo (Department of Oral and Maxillofacial Surgery, School of Dentistry, Pusan National University) ;
  • Shin, Sang-Hun (Department of Oral and Maxillofacial Surgery, School of Dentistry, Pusan National University)
  • 투고 : 2014.07.29
  • 심사 : 2014.09.02
  • 발행 : 2014.12.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Objectives: Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a side effect of bisphophonate therapy that has been reported in recent years. Osteoclastic inactivity by bisphosphonate is the known cause of BRONJ. Bone morphogenetic protein-2 (BMP-2) plays an important role in the development of bone. Recombinant human BMP-2 (rhBMP-2) is potentially useful as an activation factor for bone repair. We hypothesized that rhBMP-2 would enhance the osteoclast-osteoblast interaction related to bone remodeling. Materials and Methods: Human fetal osteoblast cells (hFOB 1.19) were treated with $100{\mu}M$ alendronate, and 100 ng/mL rhBMP-2 was added. Cells were incubated for a further 48 hours, and cell viability was measured using an MTT assay. Expression of the three cytokines from osteoblasts, receptor activator of nuclear factor-${\kappa}B$ ligand (RANKL), osteoprotegerin (OPG), and macrophage colony-stimulating factor (M-CSF), were analyzed by real-time polymerase chain reaction and enzyme-linked immunosorbent assay. Results: Cell viability was decreased to $82.75%{\pm}1.00%$ by alendronate and then increased to $110.43%{\pm}1.35%$ after treatment with rhBMP-2 (P<0.05, respectively). OPG, RANKL, and M-CSF expression were all decreased by alendronate treatment. RANKL and M-CSF expression were increased, but OPG was not significantly affected by rhBMP-2. Conclusion: rhBMP2 does not affect OPG gene expression in hFOB, but it may increase RANKL and M-CSF gene expression.

키워드

참고문헌

  1. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003;61:1115-7. https://doi.org/10.1016/S0278-2391(03)00720-1
  2. Kim HK, Kim JH, Abbas AA, Yoon TR. Alendronate enhances osteogenic differentiation of bone marrow stromal cells: a preliminary study. Clin Orthop Relat Res 2009;467:3121-8. https://doi.org/10.1007/s11999-008-0409-y
  3. Aubin J, Liu F, Bilezikian J, Raisz L, Rodan G. Principles of bone biology. 2nd ed. San Diego: Academic Press; 1996.
  4. Urist MR. Bone: formation by autoinduction. Science 1965;150:893-9. https://doi.org/10.1126/science.150.3698.893
  5. Reddi AH. Bone and cartilage differentiation. Curr Opin Genet Dev 1994;4:737-44. https://doi.org/10.1016/0959-437X(94)90141-O
  6. Reddi AH. Role of morphogenetic proteins in skeletal tissue engineering and regeneration. Nat Biotechnol 1998;16:247-52. https://doi.org/10.1038/nbt0398-247
  7. Bostrom MP, Asnis P. Transforming growth factor beta in fracture repair. Clin Orthop Relat Res 1998;(355 Suppl):S124-31.
  8. Barnes GL, Kostenuik PJ, Gerstenfeld LC, Einhorn TA. Growth factor regulation of fracture repair. J Bone Miner Res 1999;14:1805-15. https://doi.org/10.1359/jbmr.1999.14.11.1805
  9. Bessa PC, Casal M, Reis RL. Bone morphogenetic proteins in tissue engineering: the road from the laboratory to the clinic, part I (basic concepts). J Tissue Eng Regen Med 2008;2:1-13. https://doi.org/10.1002/term.63
  10. Bessa PC, Casal M, Reis RL. Bone morphogenetic proteins in tissue engineering: the road from laboratory to clinic, part II (BMP delivery). J Tissue Eng Regen Med 2008;2:81-96. https://doi.org/10.1002/term.74
  11. Chen D, Zhao M, Mundy GR. Bone morphogenetic proteins. Growth Factors 2004;22:233-41. https://doi.org/10.1080/08977190412331279890
  12. Marx RE. Clinical concerns of alendronate use. J Oral Maxillofac Surg 2008;66:1322. https://doi.org/10.1016/j.joms.2008.02.004
  13. Sahni M, Guenther HL, Fleisch H, Collin P, Martin TJ. Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. J Clin Invest 1993;91:2004-11. https://doi.org/10.1172/JCI116422
  14. Garcia-Moreno C, Serrano S, Nacher M, Farre M, Diez A, Marinoso ML, et al. Effect of alendronate on cultured normal human osteoblasts. Bone 1998;22:233-9. https://doi.org/10.1016/S8756-3282(97)00270-6
  15. Koch FP, Merkel C, Ziebart T, Smeets R, Walter C, Al-Nawas B. Influence of bisphosphonates on the osteoblast RANKL and OPG gene expression in vitro. Clin Oral Investig 2012;16:79-86. https://doi.org/10.1007/s00784-010-0477-8
  16. Sudhoff H, Jung JY, Ebmeyer J, Faddis BT, Hildmann H, Chole RA. Zoledronic acid inhibits osteoclastogenesis in vitro and in a mouse model of inflammatory osteolysis. Ann Otol Rhinol Laryngol 2003;112:780-6. https://doi.org/10.1177/000348940311200907
  17. Kwak HB, Kim JY, Kim KJ, Choi MK, Kim JJ, Kim KM, et al. Risedronate directly inhibits osteoclast differentiation and inflammatory bone loss. Biol Pharm Bull 2009;32:1193-8. https://doi.org/10.1248/bpb.32.1193
  18. Idris AI, Rojas J, Greig IR, Van't Hof RJ, Ralston SH. Amino-bisphosphonates cause osteoblast apoptosis and inhibit bone nodule formation in vitro. Calcif Tissue Int 2008;82:191-201. https://doi.org/10.1007/s00223-008-9104-y
  19. Suh DY, Boden SD, Louis-Ugbo J, Mayr M, Murakami H, Kim HS, et al. Delivery of recombinant human bone morphogenetic protein-2 using a compression-resistant matrix in posterolateral spine fusion in the rabbit and in the non-human primate. Spine (Phila Pa 1976) 2002;27:353-60. https://doi.org/10.1097/00007632-200202150-00006
  20. Kubler NR, Wurzler KK, Reuther JF, Sieber E, Kirchner T, Sebald W. Effect of different factors on the bone forming properties of recombinant BMPs. Mund Kiefer Gesichtschir 2000;(4 Suppl 2):S465-9. https://doi.org/10.1007/PL00012693
  21. Uludag H, D'Augusta D, Palmer R, Timony G, Wozney J. Characterization of rhBMP-2 pharmacokinetics implanted with biomaterial carriers in the rat ectopic model. J Biomed Mater Res 1999;46:193-202. https://doi.org/10.1002/(SICI)1097-4636(199908)46:2<193::AID-JBM8>3.0.CO;2-1
  22. Linde A, Hedner E. Recombinant bone morphogenetic protein-2 enhances bone healing, guided by osteopromotive e-PTFE membranes: an experimental study in rats. Calcif Tissue Int 1995;56:549-53. https://doi.org/10.1007/BF00298588
  23. Yamamoto M, Takahashi Y, Tabata Y. Controlled release by biodegradable hydrogels enhances the ectopic bone formation of bone morphogenetic protein. Biomaterials 2003;24:4375-83. https://doi.org/10.1016/S0142-9612(03)00337-5
  24. Toth JM, Boden SD, Burkus JK, Badura JM, Peckham SM, McKay WF. Short-term osteoclastic activity induced by locally high concentrations of recombinant human bone morphogenetic protein-2 in a cancellous bone environment. Spine (Phila Pa 1976) 2009;34:539-50. https://doi.org/10.1097/BRS.0b013e3181952695
  25. Kanatani M, Sugimoto T, Kaji H, Kobayashi T, Nishiyama K, Fukase M, et al. Stimulatory effect of bone morphogenetic protein-2 on osteoclast-like cell formation and bone-resorbing activity. J Bone Miner Res 1995;10:1681-90.
  26. Kaneko H, Arakawa T, Mano H, Kaneda T, Ogasawara A, Nakagawa M, et al. Direct stimulation of osteoclastic bone resorption by bone morphogenetic protein (BMP)-2 and expression of BMP receptors in mature osteoclasts. Bone 2000;27:479-86. https://doi.org/10.1016/S8756-3282(00)00358-6
  27. Itoh K, Udagawa N, Katagiri T, Iemura S, Ueno N, Yasuda H, et al. Bone morphogenetic protein 2 stimulates osteoclast differentiation and survival supported by receptor activator of nuclear factor-kappaB ligand. Endocrinology 2001;142:3656-62. https://doi.org/10.1210/endo.142.8.8300
  28. Zhu W, Kim J, Cheng C, Rawlins BA, Boachie-Adjei O, Crystal RG, et al. Noggin regulation of bone morphogenetic protein (BMP) 2/7 heterodimer activity in vitro. Bone 2006;39:61-71. https://doi.org/10.1016/j.bone.2005.12.018

피인용 문헌

  1. Effect of BMPs and Wnt3a co-expression on the osteogenetic capacity of osteoblasts vol.14, pp.5, 2014, https://doi.org/10.3892/mmr.2016.5734
  2. Sub‐clinical dose of bone morphogenetic protein‐2 does not precipitate rampant, sustained inflammatory response in bone wound healing vol.27, pp.4, 2014, https://doi.org/10.1111/wrr.12710